Relay Therapeutics Stock Plunges 4.41% to Monthly Low Amid Profit-Taking, Biotech Market Caution

The share price fell to its lowest level so far this month today, with an intraday decline of 4.41%.

Relay Therapeutics’ stock had reached 52-week highs multiple times in November 2025, driven by optimism around its Dynamo platform and pipeline of precision oncology candidates like RLY-2608. The company’s focus on computational drug discovery and partnerships with firms like Elevar Therapeutics positioned it as a growth story in biotech. However, recent volatility suggests a shift in investor sentiment, with the stock now trading near multi-month lows despite earlier bullish momentum.

Analysts have largely maintained positive ratings, including 10 “Buy” and 2 “Hold” recommendations as of November 2025, with price targets averaging $13.90. Yet the recent pullback may reflect profit-taking after earlier gains or broader market caution in speculative biotech stocks. A notable insider sale in late October, where R&D President Donald Bergstrom offloaded $225,000 in shares, could also weigh on confidence. Management, however, remains focused on advancing RLY-2608 into Phase 3 trials and expanding collaborations, emphasizing long-term strategic goals over short-term fluctuations.